AstraZeneca: wins patent litigation vs. ylan and Kindeva

(CercleFinance.com) - AstraZeneca has announced that it has been successful in its litigation against Mylan Pharmaceuticals Inc.

(Mylan) and Kindeva Drug Delivery LP (Kindeva), with the United States District Court for the Northern District of West Virginia, which ruled in favour of AstraZeneca.

For the record, AstraZeneca filed lawsuits against Mylan and 3M in October 2019 and against Kindeva in July 2020, alleging infringement of various US patents covering Symbicort, a bronchodilator, which, among other things, treats asthma and chronic obstructive pulmonary disease. 3M was subsequently voluntarily dismissed from the case.

The court finally determined that asserted claims in three of AstraZeneca's patents protecting Symbicort (budesonide/formoterol) in the US are not invalid.

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said, "AstraZeneca is pleased with the Court's decision, and we maintain full confidence in the strength of our intellectual property rights protecting Symbicort."


Copyright (c) 2021 CercleFinance.com. All rights reserved.